Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Britten, Carolyn D ^a   Gomes, Antoinette S ^a   Wainberg, Zev A ^a   Elashoff, David ^a   Amado, Rafael ^a   Xin, Yan ^b   Busuttil, Ronald W ^a   Slamon, Dennis J ^a   Finn, Richard S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOXORUBICIN; IODINATED POPPYSEED OIL; MICROSPHERE; MITOMYCIN C; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; EPISTAXIS; FATIGUE; FEMALE; GASTRIC ULCER BLEEDING; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOALBUMINEMIA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LUNG ANGIOGRAPHY; MALE; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PILOT STUDY; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH DISEASE; THROMBOCYTOPENIA; TUMOR VASCULARIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; LIVER TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); SURVIVAL; VASCULARIZATION;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PILOT PROJECTS; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84855743797     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-16     Document Type: Article

References (28)

1. World Health Organization. The Global Burden of Disease. 2004 Update 2008, Geneva.
2. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute 2009, Bethesda, based on November 2008 SEER data submission, posted to the SEER web site,., http://seer.cancer.gov/csr/1975_2006/
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745-750. 10.1056/NEJM199903113401001, 10072408.
4. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-1638. 10.1056/NEJMoa021423, 12711737.
5. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126:460-468. 10.1053/j.gastro.2003.10.065, 14762783.
6. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236. 10.1002/hep.20933, 16250051.
7. Llovet JM, Bruix J. Systemic review of randomized trials for unresectable hepatocellular carcinolma: Chemoembolization improves survival. Hepatology 2003, 37:429-442. 10.1053/jhep.2003.50047, 12540794.
8. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-1171. 10.1053/jhep.2002.33156, 11981766.
9. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J. Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002, 359:1734-1739. 10.1016/S0140-6736(02)08649-X, 12049862.
10. Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 2008, 49:523-529. 10.1080/02841850801958890, 18568538.
11. Finn RS, Zhu AX. Targeting angiogenesis in hepatocellular cancer: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther 2009, 9:503-509. 10.1586/era.09.6, 19374603.
12. Li X, Feng GS, Zheng CS, Zhou CK, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 2004, 10:2878-2882.
13. Chao Y, Li CP, Chau GY, Chen CP, King KL, Lui WY, Yen SH, Chang FY, Chan WK, Lee SD. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 2003, 10:355-362. 10.1245/ASO.2003.10.002, 12734082.
14. Poon RT, Ng IO, Lau C, Zhu LX, Yu WC, Lo CM, Fan ST, Wong J. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 2001, 233:227-235. 10.1097/00000658-200102000-00012, 1421205, 11176129.
15. Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004, 91:1354-1360. 10.1002/bjs.4594, 15376182.
16. Poon RT, Lau C, Yu WC, Fan ST, Wong J. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep 2004, 11:1077-1084.
17. Liao X, Yi J, Li X, Yang Z, Deng W, Tian G. Expression of angiogenic factors in hepatocellular carcinoma after transcatheter arterial chemoembolization. J Huazhong Univ Sci Technolog Med Sci 23:280-282. 200.
18. Finn RS, Bentley G, Britten CD, Amado R, Busuttil RW. Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model. Liver Int 2009, 29:284-290. 10.1111/j.1478-3231.2008.01762.x, 18482274.
19. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001, 35:421-430. 10.1016/S0168-8278(01)00130-1, 11592607.
20. Gordon MS, Margolin K, Talpaz M, Sledge GW, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001, 19:843-850.
21. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390. 10.1056/NEJMoa0708857, 18650514.
22. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J Clin Oncol 2009, 27:3027-3035. 10.1200/JCO.2008.20.9908, 2702235, 19470923.
23. Faivre SJ, Bouattour M, Dreyer C, Raymond E. Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity endpoints. J Clin Oncol 2009, 27:e248-e250. 10.1200/JCO.2009.25.0670, 19901099.
24. Atri M. New technologies and directed agents for applications of cancer imaging. J Clin Oncol 2006, 24:3299-3308. 10.1200/JCO.2006.06.6159, 16829654.
25. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ. Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:698-711. 10.1093/jnci/djn134, 18477802.
26. Siegel AB, Cohen EL, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS, Rafii S, Schwartz JD. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008, 26:2992-2998. 10.1200/JCO.2007.15.9947, 18565886.
27. Shen BQ, Li D, Oldendrop A, Eppler S, Kerns A, Beyer J, Zioncheck TF. Hepatic dysfunction resulting from common bile duct ligation did not affect bevacizumab pharmacokinetics in rats [abstract]. Proceedings of the 97th Annual Meeting of the American Association for Cancer Research: 1-5 April 2006; Washington, DC 2006, 47:731. Philadelphia (PA): AACR.
28. Trojan J, Zeuzem S. To bead or not to bead: is transartrial chemoembolization with Doxorubicin-eluting beads a new standard of care in hepatocellular carcinoma?. Gastroenterology 2010, 139:690-692. 10.1053/j.gastro.2010.06.035, 20600058.